RxDoctor Payments Data

Jose Mendez, MD

Pulmonary Disease · Danbury, CTNPI 1689651903

Payments from drug & device makers

$623in general payments, 2019–2025

Across 18 payments — averaging $34.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galvanize Therapeutics, Inc$135
  • Inspire Medical Systems, Inc.$90
  • Harmony Biosciences LLC$82
  • Jazz Pharmaceuticals Inc.$65
  • Boehringer Ingelheim International GmbH$62
  • E.r. Squibb & Sons, L.L.C.$49
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$55188%
  • Education$7312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$623 in reported general payments places this provider in the 40th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$174,877
Medicare patients
646
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate17$335,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$91,285
Breo ElliptaFluticasone/Vilanterol61$33,760
Incruse ElliptaUmeclidinium Bromide22$20,376
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$15,388
EliquisApixaban16$15,348
Spiriva HandihalerTiotropium Bromide16$11,269
SymbicortBudesonide/Formoterol Fumarate18$9,831
Combivent RespimatIpratropium/Albuterol Sulfate14$9,770
Arnuity ElliptaFluticasone Furoate15$7,413
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,039
Albuterol Sulfate HfaAlbuterol Sulfate95$2,995
Wixela InhubFluticasone Propion/Salmeterol18$2,105
Eszopiclone34$1,067
Ventolin HfaAlbuterol Sulfate12$1,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$15,34816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →